Radiomics evaluates the EGFR mutation status from the brain metastasis: a multi-center study. (21st June 2022)

• Record Type: Journal Article
• Authors: Cao, Ran; Pang, Ziyan; Wang, Xiaoyu; Du, Zhe; Chen, Huanhuan; Liu, Jiani; Yue, Zhibin; Wang, Huan; Luo, Yahong; Jiang, Xiran
• Is Part Of: Physics in medicine & biology. Volume 67:Number 12(2022)
• Publication Date: 2022-06-21
• Subjects: brain metastasis -- EGFR -- lung adenocarcinoma -- radiomics; Biophysics -- Periodicals; Medical physics -- Periodicals; 610.153
• DOI: 10.1088/1361-6560/ac7192
• Languages: English
• ISSNs: 0031-9155

Abstract

Abstract: Objective. To develop and externally validate habitat-based MRI radiomics for preoperative prediction of the EGFR mutation status based on brain metastasis (BM) from primary lung adenocarcinoma (LA). Approach. We retrospectively reviewed 150 and 38 patients from hospital 1 and hospital 2 between January 2017 and December 2021 to form a primary and an external validation cohort, respectively. Radiomics features were calculated from the whole tumor (W), tumor active area (TAA) and peritumoral oedema area (POA) in the contrast-enhanced T1-weighted (T1CE) and T2-weighted (T2W) MRI image. The least absolute shrinkage and selection operator was applied to select the most important features and to develop radiomics signatures (RSs) based on W (RS-W), TAA (RS-TAA), POA (RS-POA) and in combination (RS-Com). The area under receiver operating characteristic curve (AUC) and accuracy analysis were performed to assess the performance of radiomics models. Main results. RS-TAA and RS-POA outperformed RS-W in terms of AUC, ACC and sensitivity. The multi-region combined RS-Com showed the best prediction performance in the primary validation (AUCs, RS-Com versus RS-W versus RS-TAA versus RS-POA, 0.901 versus 0.699 versus 0.812 versus 0.883) and external validation (AUCs, RS-Com versus RS-W versus RS-TAA versus RS-POA, 0.900 versus 0.637 versus 0.814 versus 0.842) cohort. Significance. The developed habitat-based radiomics models can accurately detect the EGFR mutation in patients with BM from primary LA, and may provide a preoperative basis for personal treatment planning.